Sir,
The use of combined intravenous pulse methylprednisolone and low-dose oral cyclosporin A in the treatment of corneal graft rejection: addendum to previous report
We reported earlier the successful use of combined intravenous pulse methylprednisolone and oral cyclosporin A in the treatment of acute corneal graft rejection.
1 In our study we found a success rate of 92% in reversing graft rejection, as compared with the 80% previously reported for treatment with intravenous pulse methylprednisolone alone ? The clinical anti rejection effect of cyclosporin A may appear as early as a few hours after its commencement ? This occurred in the absence of significant serum levels of cyclosporin A, suggesting that even a low serum level of the drug may be effective. We therefore hypothesise that a lower dosage of cyclosporin A may produce similar anti rejection effects. Systemic cyclosporin A is known to be associated with various systemic side-effects, including nephrotoxicity and hypertension. 4 A lower dosage may produce fewer side-effects. A prospective pilot study was therefore undertaken to investigate whether a lower dosage of oral cyclosporin A (2 mg/kg per day with no loading dose), when used with intravenous methylprednisolone in treating corneal graft rejection, would be as effective as the previous regime (loading dose of 15 mg/kg per day for 2 days, then 7.5 mg/kg per day for another 2 days, followed by a maintenance dose to achieve a trough blood level of 100-200 fLg/l). l A total of 9 patients with acute endothelial corneal graft rejection diagnosed at the Prince of Wales Hospital between January 1997 and September 1998 were recruited, with their informed consent. Inclusion and exclusion criteria were the same as in the previous study.
1 These patients were each given Sandimmun Neoral (Sandoz) at the low dose (2 mg/kg per day with no loading dose). The intravenous methylprednisolone and 1 % prednisolone eye drops (Pred Forte, Allergan) were also given as previously described. 1 Six of the 9 patients (67%) had their acute rejection reversed ( Table  1 ). In the remaining 3 patients whose rejection did not initially respond to the low-dose regimen, the cyclosporin A dosage was increased to reach a trough blood cyclosporin A level of 100-200 fLg/l, i.e. the same as in the previous study. l Interestingly, amongst these 3 patients, 2 had their rejection reversed by the increased cyclosporin A dosage. Of the patients whose rejection initially responded to the low-dose regime, early recurrence of the rejection occurred in one (patient 9).
The recurrent rejection was eventually controlled with our previous combined regime, returning a clear graft.
The study was terminated after patient 9, in view of the apparently lower overall success rate of this low-dose Two days later he developed a small hypopyon with a central stromal infiltrate with thinned irregular epithelium but no obvious defect on fluorescein staining.
Following corneal scrapes for microbiological analysis, he was treated with intensive topical and oral ciprofloxacin, mydriatic, and flurbiprofen as a non steroidal anti-inflammatory agent. Corneal culture grew
Pseudomonas species which responded to treatment.
There had been no history of contact lens wear. At 5 months visual acuity had improved to 6/6 with a small off-axis corneal scar. 
